Press
2024-10-30
Click Therapeutics Launches Software-Enhanced Drug™ Therapies as part of new Click SE™ Offering
2024-10-08
Click Therapeutics Founder and CEO David Benshoof Klein Named to 2024 PharmaVoice 100 List
2024-09-04
Click Therapeutics Announces CT-132 Met Primary Endpoint for the Reduction of Monthly Migraine Days in ReMMi-D Pivotal Trial
2024-05-22
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
2024-04-01
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
2024-01-04
Click Therapeutics and Boehringer Ingelheim Announce FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Negative Symptoms of Schizophrenia
2024-01-03
Click Therapeutics To Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07
Click Therapeutics Announces Participation in November Investor Conferences
2023-11-06
Click Therapeutics Secures $20 Million Debt Financing from HSBC
2023-09-07
Click Therapeutics Announces Collaboration with Indivior to Develop and Commercialize Novel Prescription Digital Therapeutics in Substance Use Disorders
2023-08-03
Click Therapeutics Announces Participation in Upcoming Technology and Biotechnology Investor Events
2023-08-02
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health
2023-05-04
Click Therapeutics and Boehringer Ingelheim Initiate Pivotal Clinical Trial of Prescription Digital Therapeutics for the Treatment of Negative Symptoms in Schizophrenia
2023-04-25
Click Therapeutics Initiates Fully Remote Pivotal Trial Using Investigational Prescription Digital Therapeutics to Treat Episodic Migraine
2023-04-13
Click Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
2023-03-02
Click Therapeutics Announces Participation in Upcoming Investor Conferences
2022-12-23
Click Therapeutics Shares 2022 Accomplishments and Development Progress in its Prescription Digital Therapeutics Programs
2022-12-19
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
2022-12-16
Click Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Episodic Migraine
2022-12-06
Click Therapeutics Announces Collaboration with the Massachusetts Medical Society to Enable Advancement in Medical Innovation
2022-11-11
Click Therapeutics Announces Participation in Upcoming Investor Conferences in November and December
2022-09-14
Click Therapeutics Announces Participation in Upcoming Investor Conferences
2022-08-05
Click Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
2022-06-23
Click Therapeutics to Present at the H.C. Wainwright 1st Annual Mental Health Conference
2022-06-02
Click Therapeutics to Present at the Jefferies Healthcare Conference
2022-05-19
Click Therapeutics to Present at the UBS Global Healthcare Conference
2022-04-15
Click Therapeutics Closes $15 Million Debt Financing from Silicon Valley Bank
2022-04-07
Click Therapeutics to Present at Chardan’s Prescription Digital Therapeutics Summit
2022-03-28
Click Therapeutics Announces Formation of Scientific Advisory Board of Experts in Healthcare and Technology
2022-03-10
Click Therapeutics Provides Research and Development Updates on Its Click Neurobehavioral Intervention (CNI) Platform
2021-11-10
Click Therapeutics to Participate in the BTIG Digital Health Forum
2021-10-22
Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth Partners and Accelmed Partners
2021-04-07
Click Therapeutics Expands its Leadership with Executive and Board Appointments
2021-03-09
Click Therapeutics Announces Collaboration with youturn to Expand Access to Clinically Validated Smoking Cessation Program Clickotine®
2021-02-24
Otsuka and Click Therapeutics Initiate First-of-its-Kind Fully Remote Clinical Trial Using Digital Therapeutics as Adjunctive Therapy in Adults With Major Depressive Disorder
2020-12-01
Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations
2020-11-19
Click Therapeutics Announces that Solera Health will Provide Clinically Validated Smoking-Cessation Program Clickotine® to Blue Shield of California Members
2020-09-11
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
2020-05-11
Click Therapeutics Announces Participation in Upcoming Investor Conferences in May and June
2020-04-23
Click Therapeutics Launches New Brand Identity and Redesigned Website
2020-04-20
Magellan Health and Click Therapeutics Launch Fully Digital, Integrated and Comprehensive Smoking Cessation Program
2020-02-24
Click Therapeutics to Present at the Cowen and Company 40th Annual Healthcare Conference
2020-02-11
Click Therapeutics Announces Appointment of Top Healthcare Executives Muzammil Mansuri and Jeffrey Berkowitz as Senior Strategic Advisors and Formation of Payer Advisory Board
2019-10-16
Click Therapeutics, Inc. Honored by Goldman Sachs for Entrepreneurship
2019-09-04
Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer
2019-01-03
Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder
2018-10-02
Click Therapeutics Expands Executive Team with Chief Medical Officer and Chief Strategy Officer
2018-07-23
Sanofi Ventures Leads $17 Million Financing of Click Therapeutics
2018-06-06
Click Therapeutics Announces Multiple Publications Supporting Its Digital Therapeutic for Major Depressive Disorder; Seeking FDA Clearance
2018-05-18
Click Therapeutics Awarded National Institutes of Health (NIH) Grant for Clickotine® Digital Therapeutic Study
2017-04-25
Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder
2017-03-20
Click Therapeutics Presents Data on Increased Efficacy of a Digital Therapeutics™ Program for Smoking Cessation at Six-Month Mark of Clinical Trial
2016-09-21